Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation.
作者信息
Bleckmann Annalen, Dierks Sascha, Schildhaus Hans-Ulrich, Hellige Niels, Bacher Ulrike, Trümper Lorenz, Wulf Gerald
机构信息
Department of Haematology and Medical Oncology, University Medicine Göttingen, Göttingen, Germany.
Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
出版信息
Ann Hematol. 2021 Jan;100(1):277-279. doi: 10.1007/s00277-020-03974-y. Epub 2020 Mar 20.
Abstract
摘要
相似文献
1
Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation.
Ann Hematol. 2021 Jan;100(1):277-279. doi: 10.1007/s00277-020-03974-y. Epub 2020 Mar 20.
2
Idelalisib: targeting PI3Kδ in B-cell malignancies.
Lancet Oncol. 2014 Mar;15(3):e108. doi: 10.1016/s1470-2045(14)70052-x.
3
Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Haematologica. 2016 Mar;101(3):263-5. doi: 10.3324/haematol.2015.139246.
4
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21.
5
Idelalisib has activity in mantle cell lymphoma.
Cancer Discov. 2014 May;4(5):OF8. doi: 10.1158/2159-8290.CD-RW2014-072. Epub 2014 Mar 27.
6
FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Clin Cancer Res. 2015 Apr 1;21(7):1525-9. doi: 10.1158/1078-0432.CCR-14-2522. Epub 2015 Feb 2.
7
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Clin Cancer Res. 2015 Apr 1;21(7):1537-42. doi: 10.1158/1078-0432.CCR-14-2034. Epub 2015 Feb 10.
8
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15.
9
Idelalisib for chronic lymphocytic leukemia.
Clin Adv Hematol Oncol. 2014 Dec;12(12):846-8.
10
Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
N Engl J Med. 2015 Oct 15;373(16):1580-2. doi: 10.1056/NEJMc1507446.
引用本文的文献
1
Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR-T cell infusion.
Clin Case Rep. 2023 May 29;11(6):e7361. doi: 10.1002/ccr3.7361. eCollection 2023 Jun.
2
Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.
Cancers (Basel). 2020 May 28;12(6):1396. doi: 10.3390/cancers12061396.
本文引用的文献
1
Update on Burkitt Lymphoma.
Hematol Oncol Clin North Am. 2016 Dec;30(6):1333-1343. doi: 10.1016/j.hoc.2016.07.009.
2
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.
Oncogenesis. 2016 Oct 31;5(10):e267. doi: 10.1038/oncsis.2016.65.
3
The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.
Cell Death Discov. 2015 Oct 19;1:15044. doi: 10.1038/cddiscovery.2015.44. eCollection 2015.
4
Idelalisib for the treatment of non-Hodgkin lymphoma.
Expert Opin Pharmacother. 2016;17(2):265-74. doi: 10.1517/14656566.2016.1135130. Epub 2016 Jan 28.
5
Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Expert Rev Hematol. 2015 Oct;8(5):581-93. doi: 10.1586/17474086.2015.1071663.
6
Oncogenic mechanisms in Burkitt lymphoma.
Cold Spring Harb Perspect Med. 2014 Feb 1;4(2):a014282. doi: 10.1101/cshperspect.a014282.
7
Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.
Cancer Manag Res. 2014 Jan 9;6:27-38. doi: 10.2147/CMAR.S37745.
8
PIK3CA mutations in advanced cancers: characteristics and outcomes.
Oncotarget. 2012 Dec;3(12):1566-75. doi: 10.18632/oncotarget.716.
9
The genetic landscape of mutations in Burkitt lymphoma.
Nat Genet. 2012 Dec;44(12):1321-5. doi: 10.1038/ng.2468. Epub 2012 Nov 11.
10
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Cancer Res. 2013 Jan 1;73(1):276-84. doi: 10.1158/0008-5472.CAN-12-1726. Epub 2012 Oct 12.
Zotero 插件